Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Inclusion Criteria: * Subjects must be 18 years of age or older * Not previously treated with chemotherapy for Pancreatic Cancer * ECOG performance status of 0 or 1 * Life expectancy \> 3 months * Documentation of all sites of pancreatic disease within 28 days prior to randomization * Adequate hematological, renal, and hepatic function * Not pregnant or nursing * Fertile subjects must practice a medically approved method of contraception Exclusion Criteria: * Prior history of other malignant tumors * Participation in another investigational study within 4 weeks prior to treatment start * Major surgery within 14 days prior to treatment start * Radiation treatment within 28 days prior to treatment start * Uncontrolled cardiac atrial or ventricular arrhythmias * Gastrointestinal tract disease such resulting in an inability to take oral medication * Known to be seropositive for HIV, HBV, or HCV * Uncontrolled cancer pain